Email Alert RSS
Volume 11 Issue 5
Sep.  2020
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2020  >  11(5): 533-536
Hui-juan ZHU, Ren-zhi WANG. Clinical Diagnosis and Treatment of Pituitary Adenomas[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 533-536. doi: 10.3969/j.issn.1674-9081.2020.05.007
Citation: Hui-juan ZHU, Ren-zhi WANG. Clinical Diagnosis and Treatment of Pituitary Adenomas[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 533-536. doi: 10.3969/j.issn.1674-9081.2020.05.007
shu

Clinical Diagnosis and Treatment of Pituitary Adenomas

doi: 10.3969/j.issn.1674-9081.2020.05.007
  • 1.

    Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    The Translational Medicine Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 3.

    Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author: ZHU Hui-juan  Tel: 86-10-69155073, E-mail: shengxin2004@126.com
  • Received Date: 2020-04-20
  • Publish Date: 2020-09-30
    Abstract
  • Pituitary adenomas (PAs) are a kind of neuroendocrine neoplasm(NEN)and mostly benign. However, the hyper function of adenohypophysis and the compression to surrounding tissues and organs are often seriously presented in macroadenomas. The standardized diagnosis and treatment of PAs by multidisciplinary team is important. In 2017, the World Health Organization (WHO) revised the pathological diagnosis classification of PAs for the fourth time. High risk PAs and refractory PAs are still challenge in clinical diagnosis and treatment. The mechanism and potential therapeutic target of PAs need to be further revealed. The pathogenesis and clinical diagnosis and treatment of pituitary adenomas were reviewed.
    • FullText(HTML)
  • loading
    • References(25)
  • [1] Gittleman H, Ostrom QT, Farah PD, et al. Descriptive epidemiology of pituitary tumors in the United States, 2004—2009[J]. J Neurosurg, 2014, 121:527-535. doi:  10.3171/2014.5.JNS131819
    [2] Orija IB, Weil RJ, Hamrahian AH. Pituitary incidentaloma[J].Best Pract Res Clin Endocrinol Metab, 2012, 26: 47-68. doi:  10.1016/j.beem.2011.07.003
    [3] Fernández-Balsells MM, Murad MH, Barwise A, et al.Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis[J]. J Clin Endocrinol Metab, 2011, 96:905-912. doi:  10.1210/jc.2010-1054
    [4] Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene[J].Science, 2006, 312: 1228-1230. doi:  10.1126/science.1126100
    [5] Schöfl C, Jürgen H, Michael D, et al. Frequency of AIP gene mutations in young patients with acromegaly: a registry-based study[J].J Clin Endocrinol Metab, 2014, 99: E2789-E2793. doi:  10.1210/jc.2014-2094
    [6] Yao Y, Liu Y, Wang LJ, et al. Clinical characteristics and management of growth hormone excess in patients with McCune-Albright syndrome[J].Eur J Endocrinol, 2017, 176: 295-303. doi:  10.1530/EJE-16-0715
    [7] 王林杰, 王鸥, 潘慧, 等.多发性内分泌腺瘤病1型合并垂体腺瘤的临床特点[J].中华神经外科杂志, 2016, 32:266-269. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhsjwkzz98201603010
    [8] Tatsi C, Stratakis CA.The Genetics of Pituitary Adenomas[J].J Clin Med, 2019, 9: 30. doi:  10.3390/jcm9010030
    [9] Duong CV, Emes RD, Wessely F, et al. Quantitative, genome-wide analysis of the DNA methylome in sporadic pituitary adenomas[J].Endocr Relat Cancer, 2012, 19: 805-816. doi:  10.1530/ERC-12-0251
    [10] Osamura RY. Tumours of the Pituitary Gland[M]//Lloyd RV, Osamura RY, Klöppel G, et al.WHO Classification of Tumours of Endocrine Organs.4th ed. Lyon: International Agency for Research on Cancer, 2017: 11-64.
    [11] 袁仙仙, 朱惠娟.2017年世界卫生组织垂体肿瘤病理分类变化及临床意义[J].中华内分泌代谢杂志, 2018, 34:623-626. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnfmdx201807019
    [12] Erickson D, Scheithauer B, Atkinson J, et al. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience[J].Clin Endocrinol (Oxf), 2009, 71: 92-99. doi:  10.1111/j.1365-2265.2008.03514.x
    [13] Raverot G, Vasiljevic A, Jouanneau E, et al. A prognostic clinicopathologic classification of pituitary endocrine tumors[J].Endocrinol Metab Clin North Am, 2015, 44: 11-18. doi:  10.1016/j.ecl.2014.10.001
    [14] Villa C, Vasiljevic A, Jaffrain-Rea ML, et al. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal[J].Virchows Arch, 2019, 475: 687-692. doi:  10.1007/s00428-019-02655-0
    [15] Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas[J].Eur J Endocrinol, 2018, 178: G1-G24. doi:  10.1530/EJE-17-0796
    [16] Ho KKY, Fleseriu M, Wass J, et al. A tale of pituitary adenomas: to NET or not to NET: Pituitary Society position statement[J].Pituitary, 2019, 22: 569-573. doi:  10.1007/s11102-019-00988-2
    [17] Nasi D, Perano D, Ghadirpour R, et al. Primary pituitary neuroendocrine tumor: Case report and literature review[J].Surg Neurol Int, 2017, 8: 101. doi:  10.4103/sni.sni_450_16
    [18] Di Ieva A, Rotondo F, Syro LV, et al. Aggressive pituitary adenomas--diagnosis and emerging treatments[J].Nat Rev Endocrinol, 2014, 10: 423-435. doi:  10.1038/nrendo.2014.64
    [19] 马四海, 姚勇, 代从新, 等.替莫唑胺治疗难治性垂体腺瘤一例报告并文献复习[J].中华神经外科杂志, 2011, 27:484-488. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhsjwkzz98201105018
    [20] 中国垂体腺瘤协作组, 中华医学会神经外科学分会.中国难治性垂体腺瘤诊治专家共识(2019)[J].中华医学杂志, 2019, 99:1454-1459. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyx201919005
    [21] Goshtasbi K, Lehrich BM, Abouzari M, et al. Endoscopic versus nonendoscopic surgery for resection of pituitary adenomas: a national database study[J].J Neurosurg, 2020. doi:10.3171/2020.1.JNS193062.[Epub ahead of time].
    [22] Castinetti F.Radiation techniques in aggressive pituitary tumours and carcinomas[J].Rev Endocr Metab Disord, 2020, 21: 287-292. doi:  10.1007/s11154-020-09543-y
    [23] Zhu Y, Shaninian H, Hakimian B, et al.Temodar:novel treatment for pituitary carcinoma[J].US Endocr Soc, 2004, 138:43-45.
    [24] Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas[J].Eur J Endocrinol, 2018, 178: G1-G24. doi:  10.1530/EJE-17-0796
    [25] Lizzul L, Lombardi G, Barbot M, et al. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature[J].Pituitary, 2020, 23: 359-366. doi:  10.1007/s11102-020-01040-4
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (511) PDF downloads(64) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return